SUBSCRIBE
SUBSCRIBE

HIV

Businessman holding a dart aiming at the target - business targeting, aiming, focus concept. Art collage.
Infectious disease
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and ViiV will push forward with their long-acting antivirals after touting positive early-stage results.
March 12, 2025
 · 
2 min read
 · 
Tristan Manalac
Gilead's headquarters in Silicon Valley
Infectious disease
Anticipating Approval, Gilead Gears Up for Mid-Year Launch for Lenacapavir PrEP
Gilead beat consensus estimates in Q4 with $7.6 billion in revenue, driven largely by its HIV drug Biktarvy and CAR T therapies Trodelvy and Yescarta.
February 12, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
PRESS RELEASES
Press Releases
Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial Results
June 16, 2026
 · 
6 min read
Press Releases
U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
June 16, 2026
 · 
10 min read
Press Releases
NIH and HeroX Call for Innovative Implementation Science Approaches to Improve the Delivery and Scale-up of Long-Acting HIV Prevention and Treatment
June 11, 2026
 · 
2 min read
Press Releases
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
June 9, 2026
 · 
14 min read
Press Releases
ACTG Launches HIV Cure Study Evaluating Novel Approach Targeting the HIV Reservoir
June 4, 2026
 · 
3 min read
Press Releases
Aphios Corporation Announces Notice of Allowance for Novel Bryoid Composition Patent Targeting Alzheimer’s Disease, Multiple Sclerosis, HIV Latency and Cancer
May 26, 2026
 · 
3 min read
Press Releases
TaiMed Biologics Completes Phase 2b Enrollment for TMB-365/380 in HIV Maintenance Therapy Study
May 22, 2026
 · 
3 min read
Press Releases
Gilead Sciences Announces First Quarter Financial Results
May 8, 2026
 · 
19 min read
Press Releases
U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir
April 29, 2026
 · 
12 min read
Press Releases
Canadian First: Man Living with HIV in ‘Sustained Remission’ After Bone Marrow Transplant
April 26, 2026
 · 
6 min read
Press Releases
PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access
April 15, 2026
 · 
11 min read
Press Releases
Kashiv BioSciences Strengthens Executive Leadership with New Chief Operating Officer and Senior Vice President of Regulatory Affairs
April 15, 2026
 · 
2 min read
Press Releases
The Time to Talk about HIV is Now: ViiV Healthcare Launches “Still Here” PSA to Ignite Action Around HIV on National Youth HIV/AIDS Awareness Day
April 10, 2026
 · 
4 min read
Press Releases
Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test to further safeguard the global blood supply
March 30, 2026
 · 
4 min read
Press Releases
Tessera Therapeutics Receives Grant to Advance In Vivo Gene Writing Approaches Towards a Potential Human Immunodeficiency Virus (HIV) Cure
March 23, 2026
 · 
2 min read
Press Releases
QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention
March 20, 2026
 · 
7 min read
Press Releases
Trinity Biotech Provides Business and Trading Update
March 10, 2026
 · 
7 min read
Press Releases
ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen
February 26, 2026
 · 
4 min read
Press Releases
ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing
February 26, 2026
 · 
6 min read
Press Releases
Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy
February 26, 2026
 · 
12 min read
Load More